All stock lists
Decibel Cannabis Co Inc. (OTC:DBCCF)
CA · Delayed Price · Currency is USD
Also listed: DB.VHealthcare · Drug Manufacturers - Specialty & Generic
OTCQX since Nov 2026
$1.35-$0.04 (-2.88%)
Market cap
$51.9M
Insider Score
Health Score
Listed since
Jan 9, 2019
Website
Insider Score
––Not scored
DBCCF Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From DBCCF’s reported statements · Q2 2026 (trailing 12 months)
Profitability10 / 20
Loses money on what it sells.
- Revenue
- $127.1M
- Net income
- -$670K
- Net margin
- -0.5%
Leverage0 / 20
Heavily indebted for what it earns.
- Total debt
- $57.6M
- Cash
- $10.0M
- Net debt / EBITDA
- 19.78x
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $71.8M
- Current liabilities
- $29.4M
- Current ratio
- 2.44
Cash generation9 / 20
Roughly cash-neutral.
- Operating cash flow
- -$2.9M
- Free cash flow
- -$5.3M
- FCF margin
- -4.2%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 38.5M
- Share growth (1y)
- 0.0%
- Cash runway
- 41 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
DBCCF Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | $35.62 M | $29.92 M | $28.70 M | $32.91 M | $29.84 M | $21.24 M |
| Revenue Growth (YoY) | 19.34 % | 40.87 % | 13.40 % | 36.51 % | 34.67 % | 1.36 % |
| Cost of Revenue | $22.70 M | $22.16 M | $23.43 M | $22.65 M | $17.62 M | $12.40 M |
| Gross Profit | $12.92 M | $7.76 M | $5.27 M | $10.26 M | $12.23 M | $8.84 M |
| SG&A Expense | $10.92 M | $9.43 M | $8.78 M | $9.22 M | $8.60 M | $7.91 M |
| R&D Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expenses | $10.92 M | $9.43 M | $8.90 M | $11.18 M | $10.26 M | $9.56 M |
| Operating Income | $2.00 M | -$1.66 M | -$3.63 M | -$921.00 K | $1.97 M | -$723.00 K |
| Pretax Income | $4.18 M | -$2.18 M | -$1.33 M | -$1.34 M | $1.65 M | -$1.90 M |
| Tax Provision | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $4.18 M | -$2.18 M | -$1.33 M | -$1.34 M | $1.65 M | -$1.90 M |
| EPS (Basic) | $0.11 | -$0.06 | -$0.03 | -$0.03 | $0.04 | -$0.05 |
| EPS (Diluted) | $0.10 | -$0.06 | -$0.03 | -$0.03 | $0.04 | -$0.05 |
| Shares Outstanding | 38.47 M | 38.47 M | 38.46 M | 38.46 M | 38.46 M | 38.46 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.